PICO Portalanswers from OpenAlex
Boston Foundation
InstitutionResearch output, impact & collaborations
Boston Foundation is a institution indexed in PICO Portal from OpenAlex.
What is known about Boston Foundation?
PICO Portalrecord summary
Boston Foundation is a research organisation in Boston, US. OpenAlex records 614 works and 39,739 citations for it. 193 researchers list it as their most recent affiliation.
How many works does Boston Foundation have?
PICO Portalindexed works
Boston Foundation has 614 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Boston Foundation have?
PICO Portalcitation count
Boston Foundation has 39,739 citations in the OpenAlex counts PICO Portal stores.
How many researchers are at Boston Foundation?
PICO Portalresearcher count
Boston Foundation has 193 researchers in the PICO Portal index.
What is the average h-index at Boston Foundation?
PICO Portalavg h-index
Boston Foundation has an average h-index of 60.3 in OpenAlex.
What is the ROR of Boston Foundation?
PICO Portalror
The ROR for Boston Foundation is on the source record.
What is the OpenAlex record for Boston Foundation?
PICO Portalopenalex
The OpenAlex for Boston Foundation is on the source record.
Who are the most-cited researchers behind Boston Foundation?
PICO Portaltop researchers by citations
What are the most-cited papers on Boston Foundation?
PICO Portalmost cited works
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Menno P. Creyghton, Albert W. Cheng, G. Grant Welstead, Tristan Kooistra, Bryce W. Carey, Eveline J. Steine, Jacob H. Hanna, Michael A. Lodato, Garrett M. Frampton, Phillip A. Sharp, Laurie A. Boyer, Richard A. Young, Rudolf Jaenisch
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers, Caitlin Connelly, David Fabrizio, Laurie M. Gay, Siraj M. Ali, Riley Ennis, Alexa B. Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin W. Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi A. Garraway, Vincent A. Miller, P. J. Stephens, Garrett M. Frampton
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip Pravin Patel, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton, Alex Fichtenholtz, Geoff Otto, Kai Wang, Sean R. Downing, Jie He, Michael Schnall-Levin, Jared White, Eric M. Sanford, Peter An, James Sun, Frank Juhn, Kristina Brennan, Kiel Iwanik, Ashley Maillet, Jamie Buell, Emily White, Mandy Zhao, Sohail Balasubramanian, Selmira Terzic, Tina Richards, Vera Banning, Lázaro Ibrahim Romero García, Kristen Mahoney, Zac Zwirko, Amy Donahue, Himisha Beltran, Juan Miguel Mosquera, Mark A. Rubin, Snjezana Doğan, Cyrus V. Hedvat, Michael F. Berger, Lajos Pusztai, Matthias Lechner, Chris Boshoff, Mirna Jarosz, Christine Vietz, Alex Parker, Vincent A. Miller, Jeffrey S. Ross, John A. Curran, Maureen Cronin, Philip J. Stephens, Doron Lipson, Roman Yelensky
How much of the research on Boston Foundation is open access?
PICO Portalopen access share
83%OPEN ACCESS